Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting

October 13, 2022

https://www.globenewswire.com/news-release/2022/10/13/2533582/0/en/Editas-Medicine-Presents-Preclinical-Data-on-EDIT-103-for-Rhodopsin-associated-Autosomal-Dominant-Retinitis-Pigmentosa-at-the-European-Society-of-Gene-and-Cell-Therapy-Annual-Meeti.html

Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach

Read more at globenewswire.com

Related news for (EDIT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.